RRC ID 57972
Author Kubota E, Kataoka H, Tanaka M, Okamoto Y, Ebi M, Hirata Y, Murakami K, Mizoshita T, Shimura T, Mori Y, Tanida S, Kamiya T, Aoyama M, Asai K, Joh T.
Title ERas enhances resistance to CPT-11 in gastric cancer.
Journal Anticancer Res
Abstract BACKGROUND/AIM:We have reported that embryonic stem cell-expressed Ras (ERas) is expressed in human gastric cancer and is associated with its tumorigenicity. Here, we asked whether ERas plays a role in resistance to chemotherapy in gastric cancer.
MATERIALS AND METHODS:To assess the cytotoxicity of chemotherapeutic agents, ERas-overexpressing human gastric cancer GCIY cells were exposed to anticancer agents, including CPT-11 and inhibitor of mammalian target of rapamycin (mTOR). We also investigated the mechanisms by which ERas induces chemoresistance.
RESULTS:ERas-overexpressing clones were significantly more resistant to CPT-11 than were the control (p<0.001). Administration of rapamycin was significantly cytotoxic to the ERas-overexpressing clones compared with the control (p<0.01). Electrophoresis mobility shift assay revealed that ERas enhanced nuclear factor (NF)-κB activity. PCR array demonstrated that ERas up-regulated several multidrug efflux transporter genes, including ABCG2.
CONCLUSION:ERas induces chemoresistance to CPT-11 via activation of phosphatidylinositol-3 kinase-protein kinase β mTOR pathway and NF-κB, and consequently results in up-regulation of ABCG2.
Volume 31(10)
Pages 3353-60
Published 2011-10-1
PII 31/10/3353
PMID 21965746
MeSH Antineoplastic Agents / pharmacology Antineoplastic Agents / therapeutic use Camptothecin / analogs & derivatives* Camptothecin / pharmacology Camptothecin / therapeutic use Cell Line, Tumor Cell Proliferation / drug effects Cell Survival / drug effects DNA / metabolism DNA Topoisomerases, Type I / metabolism Drug Resistance, Neoplasm / drug effects Drug Resistance, Neoplasm / genetics Embryonic Stem Cells / drug effects Embryonic Stem Cells / metabolism* Gene Expression Profiling Gene Expression Regulation, Neoplastic / drug effects Humans Inhibitory Concentration 50 Irinotecan Models, Biological NF-kappa B / metabolism Protein Binding / drug effects Sirolimus / pharmacology Stomach Neoplasms / drug therapy* Stomach Neoplasms / genetics Stomach Neoplasms / pathology Up-Regulation / drug effects ras Proteins / metabolism*
Resource
Human and Animal Cells GCIY(RCB0555)